{"data":{"id":"us-in/ic-16-42-22-8","jurisdiction":"us-in","citation":"IC 16-42-22-8","heading":"Requirements for substitution","body":"Sec. 8. (a) For substitution to occur for a prescription other than a prescription filled under the Medicaid program (42 U.S.C. 1396 et seq.), the children's health insurance program established under IC 12-17.6-2, the biosimilar biological products requirements under IC 16-42-25, or the Medicare program (42 U.S.C. 1395 et seq.):\n(1) the practitioner must:\n(A) sign on the line under which the words \"May substitute\" appear; or\n(B) for an electronically transmitted prescription, electronically transmit the instruction \"May substitute.\"; and\n(2) the pharmacist must inform the customer of the substitution.\n(b) This section does not authorize any substitution other than substitution of a generically equivalent drug product.","path":["TITLE 16. HEALTH","ARTICLE 42. REGULATION OF FOOD, DRUGS, AND COSMETICS","Chapter 22. Drugs: Generic Drugs"],"source_url":"https://iga.in.gov/ic/2026/Title_16.html#16-42-22-8","current_through":"2026","vintage":"2026","retrieved_at":"2026-09-11T20:02:18Z","sha256":"a043473d092c4cd5be3746f508df3d45bd860e2da7c65252326f669ae7e0bab3","source_id":"us-in","stale":false,"prev":"us-in/ic-16-42-22-7","next":"us-in/ic-16-42-22-9"},"notice":"GroundRules: Original legal text. Not legal advice."}